Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 8;13:866641. doi: 10.3389/fendo.2022.866641

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Liang, Zhao, Dou, Yang, Zhao, Zhou, Zhang, Yang and Zeng

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Luteolin alleviated bone loss in OVX rats by promoting the osteogenic differentiation of BMSCs. (A) Micro-CT image of the femoral diaphysis (scale bars, 1 mm). (B) Quantitative presentation of the femoral microarchitectural parameters BMD, BV/TV, Tb.Th, Tb.N, and Tb.Sp expressed as the mean ± SD from four independent experiments. Compared with the sham group, *p < 0.05; compared with the OVX group, #p < 0.05; compared with the DG group, **p < 0.05. (C) The expression levels of osteogenesis-related marker proteins (collagen I, osteopontin and RUNX2). (D) Comparative analysis of grey values for relevant protein bands; data are expressed as the mean ± SD from three independent experiments. Compared with the sham group, *p < 0.05; compared with the OVX group, #p < 0.05; compared with the DG group, **p < 0.05. (E) BMSCs were treated with luteolin at increasing concentrations (0.05 μM, 0.1 μM, 0.5 μM, 1 μM, and 5 μM) for 24, 48 and 72 h, after which the OD value was determined by CCK-8 assay. Cell viability is expressed as the mean ± SD from four independent experiments. There was no significant difference. (F) BMSCs were treated with luteolin at increasing concentrations (0.5 μM, 1 μM, and 5 μM) for 48 h, after which osteogenesis-related marker protein (collagen I, osteopontin, RUNX2) expression was analysed with WB. (G) Comparative analysis of grey values from relevant protein bands; data are expressed as the mean ± SD from three independent experiments. Compared with the DMSO group, *p < 0.05.